

Dr. Daniel Griffin's Clinical treatment summary for 07/20/2023

Clinical Course/Treatment – COVID

COVID PASSIVE VACCINATION

COVID POST-EXPOSURE PERIOD

<https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html>

COVID- Early Viral Upper Respiratory Non-hypoxic phase – <https://www.covid.gov>

1-Paxlovid – now licensed

2 -Remdesivir -(approved for down to 28 days of age) 3-day early IV limited access,

3-Molnupiravir – <https://onlinelibrary.wiley.com/doi/10.1002/jmv.28011>

4-Conalescent Plasma - an early treatment option for the treatment of immunosuppressed COVID-19 patients at high risk for progression to severe disease who have no other treatment options, first week before you end up in the hospital.

ID Society on convalescent plasma “Recommending against the routine use of convalescent plasma among immunocompromised patients hospitalized with COVID-19.”<https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>

5-Avoid: let us not do harmful things and useless things.

COVID - Early Inflammatory Lower Respiratory Hypoxic Phase – – ‘Cytokine Storm’

1-Steroids at the right time in the right patient at the right dose. This is *after* the first week and in patients with oxygen saturations <94%. Dexamethasone 6mg a day x 6 days. *Update the HER order sets?*

2-Anticoagulation Guidelines from a number of organizations including ASH – <https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19>

3-Pulmonary support.

Dr. Daniel Griffin's Clinical treatment summary for 07/20/2023

4-Remdesivir if not on a ventilator and still in the first 10 days from symptom onset and not yet on a ventilator

Even though we have discussed the most benefit is in those first 7 day most use might be after the first 7 days and in that 7-10 day window when people are hospitalized but this applies for the first week as well. FDA approved REMDESIVIR for COVID-19 treatment in patients with severe renal impairment including those on dialysis.

“This approval for use in patients with severe renal impairment was based on results from a Phase 1 study (GS-US-540-9015), as well as results from the Phase 3 REDPINE trial that demonstrated the pharmacokinetics (PK) and safety profile of Veklury in this population. No new safety signals were observed in either of the studies.”

<https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/fda-approves-veklury-remdesivir-for-covid19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis>

5-Immune modulation: Tocilizumab, the IL6-R blocker and in some cases Baricitinib, but only if there is progression and benefits outweigh risks.

6-AVOID: unnecessary antibiotics and unproven therapies

COVID- Secondary Symptomatic Phase